株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

子宮平滑筋腫 (子宮筋腫):パイプライン製品の分析

Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 912072
出版日 ページ情報 英文 104 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.78円で換算しております。
Back to Top
子宮平滑筋腫 (子宮筋腫):パイプライン製品の分析 Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2019
出版日: 2019年09月23日 ページ情報: 英文 104 Pages
概要

当レポートでは、世界各国における子宮平滑筋腫 (子宮筋腫) 治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査しています。

イントロダクション

  • 調査範囲

子宮平滑筋腫 (子宮筋腫) - 概要

子宮平滑筋腫 (子宮筋腫) - 治療薬の開発

  • パイプラインの概要
  • 企業別のパイプライン動向
  • 大学・研究機関別のパイプライン動向
  • 企業で開発中の製品
  • 大学・研究機関で開発中の製品

子宮平滑筋腫 (子宮筋腫) - 治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

子宮平滑筋腫 (子宮筋腫) の治療薬開発に従事している企業

  • AbbVie Inc
  • Addex Therapeutics Ltd
  • Auritec Pharmaceuticals Inc
  • Bayer AG
  • BioSpecifics Technologies Corp
  • GeneScience Pharmaceuticals Co Ltd
  • Immunitor Inc
  • キッセイ薬品
  • Livzon Pharmaceutical Group Co Ltd
  • Luye Pharma Group Ltd
  • Richter Gedeon Nyrt
  • 武田薬品工業

薬剤プロファイル

子宮平滑筋腫 (子宮筋腫) - 休止中のプロジェクト

子宮平滑筋腫 (子宮筋腫) - 開発が中止された製品

子宮平滑筋腫 (子宮筋腫) - 製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

List of Tables

  • Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by AbbVie Inc, H2 2019
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Addex Therapeutics Ltd, H2 2019
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Auritec Pharmaceuticals Inc, H2 2019
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Bayer AG, H2 2019
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by BioSpecifics Technologies Corp, H2 2019
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by GeneScience Pharmaceuticals Co Ltd, H2 2019
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Immunitor Inc, H2 2019
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Kissei Pharmaceutical Co Ltd, H2 2019
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Livzon Pharmaceutical Group Co Ltd, H2 2019
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Luye Pharma Group Ltd, H2 2019
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Richter Gedeon Nyrt, H2 2019
  • Uterine Leiomyoma (Uterine Fibroids) - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
  • Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects, H2 2019
  • Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects, H2 2019 (Contd..1), H2 2019
  • Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Uterine Leiomyoma (Uterine Fibroids), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Targets, H2 2019
  • Number of Products by Stage and Targets, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
目次
Product Code: GMDHC11397IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2019, provides an overview of the Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline landscape.

Uterine fibroids are benign tumors that originate in the uterus (womb). Although they are composed of the same smooth muscle fibers as the uterine wall (myometrium), they are much denser than normal myometrium. Uterine fibroids are usually round. The most common symptoms of uterine fibroids include heavy menstrual bleeding, prolonged menstrual periods seven days or more of menstrual bleeding, pelvic pressure or pain, frequent urination, difficulty emptying bladder, constipation and backache or leg pains.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Uterine Leiomyoma (Uterine Fibroids) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline guide also reviews of key players involved in therapeutic development for Uterine Leiomyoma (Uterine Fibroids) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 3, 1, 3, 4, 1 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders).
  • The pipeline guide reviews pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Uterine Leiomyoma (Uterine Fibroids) (Non Malignant Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
    • Uterine Leiomyoma (Uterine Fibroids) - Overview
    • Uterine Leiomyoma (Uterine Fibroids) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Uterine Leiomyoma (Uterine Fibroids) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Uterine Leiomyoma (Uterine Fibroids) - Companies Involved in Therapeutics Development
    • AbbVie Inc
    • Addex Therapeutics Ltd
    • Auritec Pharmaceuticals Inc
    • Bayer AG
    • BioSpecifics Technologies Corp
    • GeneScience Pharmaceuticals Co Ltd
    • Immunitor Inc
    • Kissei Pharmaceutical Co Ltd
    • Livzon Pharmaceutical Group Co Ltd
    • Luye Pharma Group Ltd
    • Richter Gedeon Nyrt
    • Takeda Pharmaceutical Co Ltd
  • Uterine Leiomyoma (Uterine Fibroids) - Drug Profiles
    • collagenase clostridium histolyticum - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CTX-30916 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Agonize Progesterone Receptor for Uterine Fibroids - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EC-313 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • elagolix sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • leuprolide acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • leuprolide acetate SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • linzagolix choline - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NCE-403 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • relugolix - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize FSH Receptor and LH Receptor for Women's Health - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • triptorelin acetate ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • triptorelin acetate SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ulipristal acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • V3-Myoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vilaprisan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Uterine Leiomyoma (Uterine Fibroids) - Dormant Projects
  • Uterine Leiomyoma (Uterine Fibroids) - Discontinued Products
  • Uterine Leiomyoma (Uterine Fibroids) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
Back to Top